“No Association Between MAFLD, Hepatic Fibrosis, and Bone Density in Type 2 Diabetes Patients”

https://pubmed.ncbi.nlm.nih.gov/38116314

The study found that in patients with type 2 diabetes, metabolic dysfunction-associated fatty liver disease (MAFLD) and hepatic fibrosis were not significantly associated with bone mineral density or risk of osteopenia/osteoporosis independent of obesity.